Designed peptide analogues of the potassium channel blocker ShK toxin.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Biochemistry

• Publication date

  2001-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/BI011300BPMID 11747428
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone.

  2009cited by this paper
• Uniquely folded mini-protein motifs.

  2008cited by this paper
• A helical capping motif in ShK toxin and its role in helix stabilization.

  2001cited by this paper
• Structure-guided Transformation of Charybdotoxin Yields an Analog That Selectively Targets Ca2+-activated over Voltage-gated K+ Channels*

  2000cited by this paper
• The effect of deep pore mutations on the action of phenylalkylamines on the Kv1.3 potassium channel

  1999cited by this paper
• Structural Conservation of the Pores of Calcium-activated and Voltage-gated Potassium Channels Determined by a Sea Anemone Toxin*

  1999cited by this paper
• Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin.

  1999cited by this paper
• Pharmacology of voltage-gated and calcium-activated potassium channels.

  1999cited by this paper
• Ionisation behaviour and solution properties of the potassium-channel blocker ShK toxin.

  1998cited by this paper
• Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1.

  1998cited by this paper
• ShK-Dap22, a Potent Kv1.3-specific Immunosuppressive Polypeptide*

  1998cited by this paper
• Solution structure of robustoxin, the lethal neurotoxin from the funnel‐web spider Atrax robustus

  1997cited by this paper
• Ion channels in the immune system as targets for immunosuppression.

  1997cited by this paper
• On the Convergent Evolution of Animal Toxins

  1997cited by this paper
• Torsion angle dynamics for NMR structure calculation with the new program DYANA.

  1997cited by this paper
• Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin

  1996cited by this paper
• Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone

  1996cited by this paper
• Identification of three separate binding sites on SHK toxin, a potent inhibitor of voltage-dependent potassium channels in human T-lymphocytes and rat brain.

  1996cited by this paper
• An essential binding surface for ShK toxin interaction with rat brain potassium channels.

  1996cited by this paper
• MOLMOL: a program for display and analysis of macromolecular structures.

  1996cited by this paper
• AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR

  1996cited by this paper
• Minimization of a Polypeptide Hormone

  1995cited by this paper
• Characterization of a potassium channel toxin from the Caribbean Sea anemone Stichodactyla helianthus.

  1995cited by this paper
• The program XEASY for computer-supported NMR spectral analysis of biological macromolecules

  1995cited by this paper
• Site-specific chemical modification procedures.

  1994cited by this paper
• A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis.

  1990cited by this paper
• Synthesis, biological activity and conformational analysis of cyclic GRF analogs.

  1988cited by this paper
• Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides.

  1970cited by this paper
• Tissue sulfhydryl groups.

  1959cited by this paper

• Pharmacological Approaches to Studying Potassium Channels.

  2021cites this paper
• Defensins, a novel type of animal toxin‐like potassium channel inhibitor

  2019cites this paper
• Structure, folding and stability of a minimal homologue from Anemonia sulcata of the sea anemone potassium channel blocker ShK

  2018cites this paper
• Immune drug discovery from venoms

  2018cites this paper
• Treating autoimmune disorders with venom-derived peptides

  2017cites this paper
• Novel Methods for the Chemical Synthesis of Insulin Superfamily Peptides and of Analogues Containing Disulfide Isosteres.

  2017cites this paper
• Endogenous animal toxin-like human β-defensin 2 inhibits own K+ channels through interaction with channel extracellular pore region

  2015cites this paper
• Enhanced synthetic methods and stabilization of insulin-like peptides

  2015cites this paper
• Total Chemical Synthesis of a Heterodimeric Interchain Bis-Lactam-Linked Peptide: Application to an Analogue of Human Insulin-Like Peptide 3

  2013cites this paper
• Strategies for the Development of Conotoxins as New Therapeutic Leads

  2013cites this paper
• Lactam-stabilized helical analogues of the analgesic μ-conotoxin KIIIA.

  2011cites this paper
• Role of Disulfide Bonds in Peptide and Protein Conformation

  2011cites this paper
• µ-Conotoxins as Leads in the Development of New Analgesics

  2010cites this paper
• Structurally Minimized μ‐Conotoxin Analogues as Sodium Channel Blockers: Implications for Designing Conopeptide‐Based Therapeutics

  2009cites this paper
• Conotoxins containing nonnatural backbone spacers: cladistic-based design, chemical synthesis, and improved analgesic activity.

  2007cites this paper
• mab-7 encodes a novel transmembrane protein that orchestrates sensory ray morphogenesis in C. elegans.

  2007cites this paper
• Venom therapy in multiple sclerosis.

  2007cites this paper
• K+ channel blockers: novel tools to inhibit T cell activation leading to specific immunosuppression.

  2006cites this paper
• Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.

  2004cites this paper
• Electrophysiological effects of anthopleurin-Q on rat hepatocytes.

  2004cites this paper
• Substitution of a single residue in Stichodactyla helianthus peptide, ShK-Dap22, reveals a novel pharmacological profile.

  2003cites this paper